Inhibition of  HAX-1  by miR-125a reverses cisplatin resistance in laryngeal cancer stem cells

Jiajia Liu; Qinglai Tang; Shisheng Li; Xinming Yang

doi:10.18632/oncotarget.13424

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Inhibition of HAX-1 by miR-125a reverses cisplatin resistance in laryngeal cancer stem cells

Jiajia Liu, Qinglai Tang _, Shisheng Li and Xinming Yang

PDF | HTML | How to cite

Oncotarget. 2016; 7:86446-86456. https://doi.org/10.18632/oncotarget.13424

Metrics: PDF 2105 views | HTML 2666 views | ?

Abstract

Jiajia Liu1, Qinglai Tang1, Shisheng Li1, Xinming Yang1

1Department of Otolaryngology, Head and Neck Surgery, the Second Xiangya Hospital, Central South University, Changsha 410011, China

Correspondence to:

Qinglai Tang, email: [email protected]

Keywords: laryngeal cancer stem cells, microRNA-125a, HAX-1, cisplatin, chemoresistance

Received: October 21, 2016 Accepted: November 07, 2016 Published: November 17, 2016

ABSTRACT

Chemoresistance is a major obstacle in chemotherapy of laryngeal carcinoma. Recently, studies indicate that cancer stem cells are responsible for chemotherapy failure. In addition, microRNAs play important roles in tumor initiation, development and multidrug resistance. In the present study, we found that the expression of microRNA-125a was decreased in laryngeal carcinoma tissues and Hep-2 laryngeal cancer stem cells (Hep-2-CSCs). MicroRNA-125a gain-of-function significantly increased the sensitivity of Hep-2-CSCs to cisplatin in vitro and in vivo. Combination with microRNA-125a mimics can decrease the half maximal inhibitory concentration of Hep-2-CSCs to cisplatin. Mechanically, we found that microRNA-125a reverses cisplatin resistance in Hep-2-CSCs by targeting Hematopoietic cell-specific protein 1-associated protein X-1 (HAX-1). Inhibition of HAX-1 by microRNA-125a significantly promotes the cisplatin-induced apoptosis in Hep-2-CSCs through mitochondrial pathway. In addition, multidrug resistance of Hep-2-CSCs to vincristine, etoposide and doxorubicin was greatly improved after the cells were transfected with microRNA-125a mimics. These dates strongly suggested the promotion of microRNA-125a/HAX-1 axis on chemotherapy of laryngeal carcinoma.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13424

Publication Alerts

Oncoscience

Post-Publication Promotion

Research Papers:

Inhibition of HAX-1 by miR-125a reverses cisplatin resistance in laryngeal cancer stem cells

Abstract